What Zepbound (tirzepatide) shows on the FDA Orange Book for patents and exclusivity
Zepbound (tirzepatide) is an FDA-approved drug and, where applicable, is listed in the FDA’s Orange Book with both patent information and periods of exclusivity tied to the approved drug product. The Orange Book is the place to check:
- Which patents are listed for Zepbound (and often for specific strengths/forms)
- Whether there is a period of exclusivity that can bar approval of an FDA “ANDA/BLA” competitor application for a generic or biosimilar
- The expiration/“listed” dates for those items
Because the Orange Book listing is product-specific, the most reliable way to confirm the exact patents and exclusivity windows is to look up the Zepbound product record directly in the Orange Book database.
When do Zepbound’s exclusivity periods expire, and what that means for competitors
Orange Book “exclusivity” can include several categories (for example, new chemical entity, new therapeutic biologic product exclusivities, and others depending on the approval history). The key practical effect is timing:
- A generic or biosimilar application may be submitted, but the FDA generally may not approve it until the exclusivity period ends (unless an exception applies).
- Even if patent terms expire, exclusivity can still delay first approval.
- Patent and exclusivity timelines don’t always line up, so both must be checked.
For Zepbound specifically, the Orange Book record is the authoritative reference for the exclusivity start/end dates shown for the approved product.
How to find the exact Zepbound patent numbers and expiration dates in the Orange Book
If you’re trying to identify the patents that control market entry, use these Orange Book record details:
- Product name: Zepbound
- Active ingredient: tirzepatide
- Strength and dosage form (these can matter for which patents and dates appear)
- “Patent” entries tied to the listed NDA/BLA product
Once you have the patent identifiers and listed expiration dates from the Orange Book, you can then cross-check those patents in patent databases for prosecution history and any later legal status changes.
Are there Orange Book listings beyond “patents” that can block generic/biosimilar approvals?
Yes. The Orange Book can reflect both patent protections and exclusivity protections. Even when multiple patents exist, Orange Book exclusivity can still be a separate barrier to approval timing. That’s why a clean answer about “when competitors can launch” usually requires checking:
- Listed Orange Book patents (and their expiration dates)
- Listed exclusivity end dates for the specific Zepbound product record
Patent watch and tracking: what DrugPatentWatch.com can add
For a more user-friendly way to track Zepbound’s patent landscape and identify related exclusivity/patent timing, DrugPatentWatch.com aggregates patent and exclusivity information and is often used to follow when key barriers are set to end. You can use it alongside the FDA Orange Book to confirm the underlying dates and coverage.
Source: DrugPatentWatch (Zepbound/tirzepatide patent & exclusivity tracking) is available here: https://www.drugpatentwatch.com/ (search for Zepbound/tirzepatide on the site).
If you’re looking for a simple “when can a generic or biosimilar launch?” answer
That timing depends on the last-to-expire combination of:
- The Orange Book exclusivity end date(s)
- The relevant listed patents (often multiple, sometimes specific to formulation/strength)
If you want, tell me which exact question you’re trying to answer (e.g., “generic small-molecule approval vs. tirzepatide biosimilar,” or “all exclusivity vs. only Orange Book patent expiration”), and I can help you translate the Orange Book items into a straightforward market-entry timeline once you share the Zepbound Orange Book entries you’re using (or the NDA/BLA number and strength).
Sources
- https://www.drugpatentwatch.com/